Influence of patients’ characteristics and disease management on asthma control - 20/08/11
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/lowast.gif)
Lyon and Montpellier, France
Abstract |
Background |
Although asthma control is a major outcome in disease management, little is known about its determinants.
Objectives |
We sought to study the relationships between asthma control and patient characteristics or asthma management.
Methods |
Asthmatic patients (age 18-50 years) who were regular customers of pharmacies and had a prescription for an antiasthma medication were recruited consecutively. Patients completed a questionnaire, which was complemented by computerized pharmacy records of previously dispensed medications. Asthma control (adequate/inadequate) was assessed with the Asthma Control Test. Determinants of asthma control were identified by means of multivariate logistic regression analysis.
Results |
The mean age of the 1351 patients included was 36.8 years (SD, 9.8), and 55.8% were women. A minority of patients were considered to have had their symptoms adequately controlled. Smoking, female sex, and a body mass index of greater than 30 kg/m2 were all independent determinants of inadequate control. Compared with patients receiving inhaled corticosteroid monotherapy, those who were dispensed fixed combinations of inhaled corticosteroids and long-acting β-agonists presented with a significantly lower risk of inadequate asthma control (odds ratio, 0.58; 95% CI, 0.35-0.96).
Conclusion |
Asthma control varied according to both the patients’ characteristics and therapy.
Clinical implications |
Our results strongly support the need to improve asthma control, especially in primary care and in women. A regular use of fixed controller combinations, helping patients to quit smoking, or addressing weight issues might contribute to improvement in asthma control.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, control, therapy, sex, smoking, primary care
Abbreviations used : ACT, BMI, GP, ICS, LABA
Plan
Supported in part by a nonconditional grant from GSK France. Disclosure of potential conflict of interest: J. Bousquet has consultant arrangements with AstraZeneca, GlaxoSmithKline, Merck, Sharp, and Dhome and is on the speakers’ bureau for AstraZeneca, GlaxoSmithKline, Merck, Sharp, and Dhome. The rest of the authors have declared that they have no conflict of interest. |
Vol 117 - N° 6
P. 1404-1410 - juin 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?